Myriad Genetics, Inc. MYGN R2K
Company Overview
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.33.
Recent Developments
- Dec 2025 Revenue of $824.50M (-1.6% YoY); net profit $-365.90M.
- Trailing 12 Months Year-on-year growth — revenue -20.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.60% |
| 1 Year: | -20.80% |
Stock Price Performance
| 1 Year: | +15.71% |
| 6 Months: | -8.21% |
| 3 Months: | +31.59% |
| 1 Month: | +30.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 26.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MYGN Myriad Genetics, Inc. R2K | 6.04 | -1.40 | $570.47M | 0.00% | -67.60% | -23.51% | 5.60% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 178.90M | 196.70M | 194.70M | 199.60M | 178.80M | 187.90M | 183.10M | 193.90M | 202.30M | 216.80M | 216.60M | 215.40M | 186.30M | 195.10M | 164.00M | 93.20M | 145.20M | 173.10M | 189.40M | 167.30M | 164.90M | 179.30M | 156.40M | 181.20M | 183.50M | 191.90M | 202.20M | 211.50M | 213.30M | 195.90M | 213.10M | 205.70M | 200.40M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.60M | 147.10M | 149.80M | 134.20M | 151.80M | 143.80M | 137.60M |
| Operating Income | 55.29M | 25.90M | 36.30M | 35.70M | 43.30M | 45.20M | 42.60M | 7.10M | 17.20M | 5.50M | 18.90M | 84.00M | 6.30M | 13.80M | 17.80M | 1.20M | 6.10M | 5.90M | -5.60M | -20.90M | -8.80M | -133.70M | -68.30M | -39.60M | -46.70M | -20.80M | -79.90M | -25.60M | -17.80M | -45.00M | -52.20M | -113.70M | -60.10M | -27.90M | -36.50M | -20.00M | -29.00M | -329.20M | -23.30M | -30.70M |
| Net Income | 36.77M | 16.00M | 24.00M | 21.40M | 30.30M | 37.10M | 34.50M | -700.00K | 6.10M | 2.80M | 12.30M | 78.80M | 30.90M | 9.10M | 14.50M | -700.00K | 2.60M | 6.90M | -4.20M | -20.60M | -8.30M | -115.20M | -55.40M | -15.20M | -39.50M | -4.70M | 24.60M | -20.50M | -14.10M | -35.10M | -54.70M | -116.10M | -61.30M | -26.00M | -36.70M | -22.10M | -100.00K | -330.50M | -27.40M | -34.10M |
| Diluted EPS | 0.48 | 0.21 | 0.32 | 0.29 | 0.42 | 0.50 | 0.47 | -0.01 | 0.09 | 0.04 | 0.18 | 1.12 | 0.43 | 0.13 | 0.20 | -0.01 | 0.03 | 0.09 | -0.06 | -0.28 | -0.11 | -1.55 | -0.74 | -0.20 | -0.52 | -0.06 | 0.30 | -0.26 | -0.18 | -0.43 | -0.67 | -1.42 | -0.75 | -0.29 | -0.41 | -0.24 | 0.00 | -3.57 | -0.29 | -0.36 |
| R&D Expense | 13.40M | 22.60M | 17.50M | 16.70M | 17.20M | 16.70M | 17.20M | 19.40M | 18.60M | 17.60M | 18.80M | 17.80M | 16.80M | 18.50M | 17.70M | 21.10M | 22.40M | 21.50M | 20.90M | 21.30M | 18.80M | 19.70M | 17.40M | 17.60M | 23.10M | 19.50M | 18.80M | 21.20M | 20.30M | 20.50M | 22.50M | 21.20M | 24.00M | 24.90M | 27.10M | 28.50M | 27.50M | 25.60M | 28.20M | 27.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 326.53M | 362.65M | 402.08M | 496.00M | 613.20M | 778.20M | 722.50M | 740.50M | 728.70M | 743.70M | 851.10M | 638.60M | 557.10M | 690.60M | 678.40M | 753.20M | 837.60M | 824.50M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 476.40M | 517.00M | 585.40M | 576.60M |
| Operating Income | 126.46M | 135.07M | 157.78M | 180.32M | 228.00M | 274.40M | 133.60M | 153.40M | 44.00M | 121.90M | 7.60M | -231.70M | -289.70M | -190.50M | -140.60M | -257.40M | -123.50M | -387.20M |
| Net Income | 84.61M | 152.30M | 100.71M | 112.15M | 147.20M | 176.20M | 79.80M | 117.20M | 17.40M | 133.30M | 4.60M | -199.50M | -223.60M | -27.20M | -112.00M | -263.30M | -127.30M | -365.90M |
| Diluted EPS | 0.86 | 1.54 | 1.10 | 1.30 | 1.77 | 2.25 | 1.07 | 1.60 | 0.25 | 1.85 | 0.06 | -2.69 | -2.99 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 |
| R&D Expense | 17.91M | 21.87M | 27.75M | 42.65M | 53.70M | 67.50M | 75.50M | 70.60M | 74.40M | 70.80M | 85.90M | 77.20M | 73.30M | 81.90M | 85.40M | 88.70M | 113.40M | 106.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 593.85M | 610.83M | 690.63M | 803.82M | 823.80M | 766.20M | 880.50M | 1.21B | 1.18B | 1.56B | 1.40B | 1.42B | 1.32B | 1.20B | 1.15B | 1.03B | 706.60M |
| Total Equity | 425.65M | 434.22M | 557.58M | 566.79M | 635.80M | 728.60M | 719.00M | 661.70M | 739.60M | 768.40M | 966.10M | 1.09B | 918.20M | 881.00M | 967.80M | 885.80M | 783.20M | 701.10M | 368.00M |
| Cash & Equivalents | 237.73M | 63.51M | 92.84M | 52.68M | 86.40M | 104.10M | 64.80M | 64.10M | 68.50M | 102.40M | 110.90M | 93.20M | 163.70M | 117.00M | 257.40M | 56.90M | 132.10M | 102.40M | 149.60M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 99.10M | 9.30M | 233.50M | 224.40M | 224.80M | 0 | 0 | 38.50M | 39.60M | 119.90M |
| Total Liabilities | - | - | 36.27M | 44.03M | 54.98M | 75.23M | 104.80M | 104.10M | 132.40M | 440.90M | 209.20M | 473.80M | 486.40M | 537.80M | 352.90M | 312.90M | 363.30M | 326.50M | 338.60M |
| Current Liabilities | - | - | 27.47M | 34.39M | 44.97M | 64.51M | 80.60M | 68.70M | 72.30M | 217.50M | 102.20M | 117.80M | 147.00M | 145.90M | 204.30M | 137.20M | 155.90M | 164.10M | 133.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 84.04M | 155.09M | 130.83M | 141.80M | 173.87M | - | - | 166.30M | 106.20M | 115.90M | 83.70M | 60.70M | 18.60M | -106.30M | -110.90M | -8.70M | 1.80M |
| Investing Cash Flow | -206.34M | -76.67M | -54.39M | -38.89M | -75.59M | - | - | -91.40M | -146.30M | -11.60M | -286.40M | 19.30M | 274.40M | -77.50M | 31.90M | -11.90M | -27.40M |
| Financing Cash Flow | -51.92M | -49.09M | -116.60M | -69.25M | -80.56M | - | - | -68.30M | 71.80M | -95.00M | 182.30M | -10.00M | -150.60M | -8.00M | 152.90M | -7.40M | 64.20M |
| Share Buybacks | - | 71.39M | 200.49M | 128.47M | 146.30M | 287.70M | 210.70M | 162.60M | 31.60M | - | 50.00M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70.2% | 68.6% | 69.9% | 69.9% |
| Operating Margin % | 38.7% | 37.2% | 39.2% | 36.4% | 37.2% | 35.3% | 18.5% | 20.7% | 6.0% | 16.4% | 0.9% | -36.3% | -52.0% | -27.6% | -20.7% | -34.2% | -14.7% | -47.0% |
| Net Margin % | 25.9% | 42.0% | 25.0% | 22.6% | 24.0% | 22.6% | 11.0% | 15.8% | 2.4% | 17.9% | 0.5% | -31.2% | -40.1% | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% |
| ROE % | 19.5% | 27.3% | 17.8% | 17.6% | 20.2% | 24.5% | 12.1% | 15.8% | 2.3% | 13.8% | 0.4% | -21.7% | -25.4% | -2.8% | -12.6% | -33.6% | -18.2% | -99.4% |
| ROCE % | - | 23.8% | 27.4% | 27.9% | 30.8% | 36.9% | 19.2% | 19.0% | 4.4% | 11.4% | 0.5% | -18.4% | -22.8% | -17.1% | -13.2% | -26.0% | -14.3% | -67.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.41% | 8.89M | $55.03M |
| 2 | Millennium Management Llc | 7.06% | 6.67M | $41.28M |
| 3 | Glenview Capital Management, Llc | 5.73% | 5.41M | $33.50M |
| 4 | Shaw D.E. & Co., Inc. | 4.76% | 4.50M | $27.85M |
| 5 | State Street Corporation | 4.68% | 4.42M | $27.38M |
| 6 | Vanguard Capital Management LLC | 4.16% | 3.92M | $24.29M |
| 7 | Morgan Stanley | 3.36% | 3.17M | $19.61M |
| 8 | Vanguard Portfolio Management LLC | 2.73% | 2.58M | $15.98M |
| 9 | Goldman Sachs Group Inc | 2.51% | 2.37M | $14.65M |
| 10 | Orbimed Advisors LLC. | - | 125.00M | $773.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MYGN
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNRDlSQ2d4NV9Eem9rRHZ5dWlVaS0zcllFOEpUYUQ1dzhYZzJQUzRwTlhFMVJUNkdxNDRYTlZ1NW11S2ZKeVZOQndVWW5qOUY3R2FreTVGeHFhaTBSRHlCRldiclQzU3FmdndhdlloS0FidmlQWkxrYXg3bEFoaTdNRG5IVG9WZ21zWFd3cD…
Myriad Genetics (MYGN) Proxy filing Summary - Quartr
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1DbWZOQk9qLS1YMmg1eEVTYXlYak9KcVU2cVlCckcwbkRRUVdBcmZMUldpbVFvRDJCQ1YwQmJIYUxJbjA5REctWnVIZDdjM1ZEMFlsbmdBMXFPOWtlVU5BZ1RfMXVuTjdKQTRBLWJjTzc4UDJtQkE4?oc=5" target="_blank">Myriad …
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNNXZYNHFCdG5ac2htU3RoRk1BYTJrU0tmR0FCakFnVUZCQk9iWjZidGtGZnZFdFJwZXdOdjBQLTVWZnFZSVBzTVBOc2kyYmpfZG8xRUZPWXk3cFhTbF9hQ1RtOXJEYVBHQkc3Y1dRR1lsY1RJcjNnMTktaXRDVnNrbVNmODlvQmFQdlVoUl…
Myriad widens cancer test access as breast study bolsters its case - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOXltS1FNRWxXV2NvN3g1ZW9sdU01YkU1Wkp0VEl3VzRTdkl6eUh4VW1YQWNvRHAwVUJJcGpOVkQxWkdlamsybE0zLS1PbDlPZ2d2akxHM3dkai1kUjUtRmZLLW5uTG4tZ0UwTW1jXzN1RWpjb1NqTlRZYzVtYW84UkF5VEFEY193c1RiQj…
Myriad Genetics in record sell-off after Q1 miss - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOMXpsS2ZOdDc5RXhJMWxndWU2bk5YR1ZSQXc1dHowOVczR1g3eG4zS1RhU1ZVTlM4eHNNUTREbFJEbnVLTnRQV1NjNWtmQ3dMbmlHS1RxeS1kNEE4eDlVYk1rUHRKNGJCMm9lc1lvWFZqRnNucW90aTBsT1hhTW5fR0RRM3NKbVl6b1E?oc…
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins - StockStory
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOanZoN3VjQkJMWkFJYXpVcDBNTHFNQmhhQkVYZkNyZnRaOWRkYTVZY3FudlpfbGJjZFVDYjJxZWJCaHVLbFlscFMyYnM5Tks1UEgxakdXbmp0RElmNlZYOUFIRVExMUhKRzVmdkdZdklsRmRMcmNpcUZKU0Z4OGNzQVUtOEo0MFZyX19YYi…
MYGN — Frequently Asked Questions
What is the current share price of Myriad Genetics, Inc. (MYGN)?
As of 2026-07-14 21:23 PDT, Myriad Genetics, Inc. (MYGN) trades at $6.04 on NasdaqGS. Its 52-week range is $3.55 to $8.18.
What is the market capitalisation of MYGN?
Myriad Genetics, Inc. (MYGN) has a market capitalisation of $570.47M on NasdaqGS.
What is the P/E ratio of MYGN?
MYGN trades at a trailing price-to-earnings (P/E) ratio of -1.40. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.21.
What is the return on equity (ROE) of MYGN?
MYGN has a return on equity (ROE) of -23.51%. Its return on capital employed (ROCE) is -67.60%.
Is MYGN a good stock to buy?
This page provides a data-driven analysis of Myriad Genetics, Inc. (MYGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.